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Previewspancreatic islet cells and on other enter-
oendocrine cells may complicate the
picture.
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Adiponectin and its receptors, AdipoR1 and AdipoR2, regulate glucose and fatty acid metabolism via activa-
tion of AMP-activated protein kinase. Recent work inNature (Iwabu et al., 2010) demonstrates that adiponec-
tin induces a marked Ca2+ influx in skeletal muscle via AdipoR1 to control mitochondrial biogenesis, reduce
oxidative stress, and enhance endurance capacity.The term adipokine was coined to
describe signaling messengers that are
secreted from adipocytes, of which the
two most abundant are leptin and adipo-
nectin. Because adiponectin levels are
decreased in human obesity and type 2
diabetes, this adipokine has generated
enormous interest within the scientific
community. It has previously been shown
that adiponectin-deficient mice exhibited
insulin resistance (Maeda et al., 2002)
and that exogenous administration of
adiponectin lowered circulating glucose
and ameliorated insulin resistance (Berg
et al., 2001; Fruebis et al., 2001) via a
process thought to involve activation of
AMP-activated protein kinase (AMPK).
Recent work published in Nature (Iwabu
et al., 2010) now identifies a novel mecha-
nism by which adiponectin protects
against skeletal muscle insulin resistance
(Figure 1).
In 2003, Kadowaki and colleagues
reported the cloning of complementary
DNAs encoding adiponectin receptors 1
and 2 (Adipor1 and Adipor2) (Yamauchiet al., 2003). They found that AdipoR1 is
abundantly expressed in skeletal muscle
and liver, whereas AdipoR2 is predomi-
nantly expressed in the liver. Intriguingly,
both receptors were predicted to con-
tain seven-transmembrane domains but
were unlike G protein coupled in struc-
ture. Nonetheless, these novel receptors
maintained functionality because subse-
quent studies identified that disruption of
the adiponectin receptors AdipoR1 and
AdipoR2 abrogated adiponectin’s meta-
bolic actions (Yamauchi et al., 2007).
As insulin resistance has been linked to
mitochondrial dysfunction, many strate-
gies have been employed to improve
mitochondria function (e.g., upregulate
fatty acid oxidation rates, increase fatty
acid uptake, etc.) or increase mitochon-
dria number (mitochondrial biogenesis).
AMPK is activated when the energy
charge of the cell is low, such as during
fasting or following exercise. AMPK is
well known to stimulate an increase in
fatty acid oxidation via phosphorylation
of acetyl-CoA-carboxylase (ACC) andto upregulate mitochondrial biogenesis
through the master regulator peroxisome
proliferator-activated receptorg coactiva-
tor-1a (PGC-1a) (Ja¨ger et al., 2007). The
metabolic effects of AMPK and adiponec-
tin are similar in insulin-sensitive tissues,
and it was no surprise that, indeed, adipo-
nectin was found to regulate glucose utili-
zation and fatty acid combustion through
AMPK (Yamauchi et al., 2002). Another
cellular energy sensor, the nicotinamide
adenine dinucleotide (NAD+)-dependent
histone deacetylase silent information
regulator of transcription (SIRT1), is also
able to activate PGC-1a by deacetylation
(Lagouge et al., 2006). Because SIRT1 is
able to activate an upstream activating
AMPK kinase, LKB1, strong links between
AMPK, SIRT1, PGC-1a, and consequently
mitochondrial biogenesis and function are
emerging.
The recent study published in Nature
(Iwabu et al., 2010) has added to our
understanding of the mechanism of action
of adiponectin and adipoR1 in skeletal
muscle. These authors provide detailed11, June 9, 2010 ª2010 Elsevier Inc. 447
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Figure 1. Adiponectin-Mediated Oxidative Phenotype via AdipoR1 and Calcium
Iwabu et al. (2010) propose that, in skeletal muscle, adiponectin induces extracellular Ca2+ influx by
AdipoR1. This calcium influx sets off a chain of events whereby PGC1-a can be activated through both
the CaMK pathway and via AMPK and SIRT1, leading to increased oxidative capacity. The mechanism
by which adiponectin and AdipoR1 increase Ca2+ influx into cells remains to be fully determined.
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AdipoR1 to AMPK, SIRT1, and PGC-1a.
Most interesting is the observation that
adiponectin induces calcium (Ca2+) influx
into myotubes via AdipoR1, which acti-
vates Ca2+/calmodulin-dependent pro-
tein kinase kinase b (CaMKKb), AMPK,
SIRT1, and PGC-1a to subsequently
increase mitochondrial biogenesis. Fur-
thermore, muscle-specific disruption of
AdipoR1 in mice in vivo suppressed
these effects, resulting in insulin resis-
tance and decreased exercise endurance
capacity.
Muscle-specific disruption of AdiopR1
(muscle-R1KO) mice produced a pheno-
type that was consistent with impaired
oxidative capacity. This was characterized
by decreased mitochondria DNA content,
oxidative type 1 myofibers, expression
levels of oxidative phosphorylation and
mitochondrial genes, pAMPK and PGC-
1a protein expression, b-oxidation, and
a decrease in exercise endurance perfor-
mance compared with control animals.448 Cell Metabolism 11, June 9, 2010 ª2010Analysis of 24 hr oxygen consumption
revealed a decrease in whole-body
oxygen consumption. Intriguingly, given
such a strong oxidative phenotype, the
respiratory quotient (RQ), a measure of
substrate utilization, was not different
when comparing muscle-R1KO with con-
trol mice. As skeletal muscle oxidative
capacity and insulin sensitivity are inextri-
cably linked, it seemed likely that the
muscle-R1KO mice would have metabolic
abnormalities. Indeed, glucose and insulin
homeostasis was disrupted in these
animals, as measured by oral glucose
tolerance test, insulin tolerance test, and
hyperinsulinaemic euglycaemic clamp
studies. Signaling in the muscle suggested
that the decrease in insulin sensitivity was
due to impaired tyrosine phosphorylation
of IRS-1 and decreased phosphorylation
of Akt. Because body weight, lean body
mass, or fat mass were not reported in
this study, it is not clear whether the
decreased insulin action in muscle-R1KO
mice was linked to obesity.Elsevier Inc.Iwabu and colleagues next performed
in vitro studies in the skeletal muscle
C2C12 cells treated with adiponectin.
Adiponectin treatment increased PGC1-a
and mitochondrial DNA content. In a series
of studies using specific short interfering
RNAs (siRNAs), suppression of AdipoR1,
CaMKKb, AMPKa1 and 2 (in combination),
PGC1a, or SIRT1 blunted the ability of adi-
ponectin to increase mitochondrial DNA,
whereas siRNAs of AdipoR1 and CaMKKb
inhibited the ability of adiponectin to
induce PGC1-a mRNA expression. Most
importantly, adiponectin appears to be
necessary to signal withAdipoR1 to initiate
Ca2+ influx. Calcium plays a pivotal role in
the exercise response, particularly with
contraction-induced glucose uptake, and
is also involved in fatty acid oxidation. Adi-
ponectin-induced Ca2+ influx in the C2C12
cells was required for CaMKK and AMPK
activation and for PGC1-a expression.
In light of these results, the authors
revisited the muscle-R1KO mice and ob-
served impairment in adiponectin-induced
calcium influx. As such, it would appear
that Ca2+ influx is driving the adiponectin/
adipoR1-stimulated intracellular signaling
cascade. One important yet-to-be deter-
mined question is what is the mechanism
by which adiponectin and AdipoR1 in-
crease Ca2+ influx into the myotube? Is
this a direct function of AdipoR1’s unusual
seven-transmembrane domain with an
intracellular amino terminus? Or is/are
second messenger molecule(s) needed
downstream of the receptor, and if so,
which ones? More studies are required to
delineate this mechanism.
Physical activity programs are success-
ful in influencing weight loss and improving
insulin sensitivity in human obesity, but
such programs are only mildly successful
due to low continual compliance rates. As
such, developing drugs that act as ‘‘exer-
cise mimetics’’ have long been an aim of
many researchers. Of note, adiponectin is
one of many factors that increase with
exercise. Iwabu et al. (2010) exercise
trained the muscle-R1KO mice to examine
whether simultaneous activation of Ca2+
signaling and AMPK/SIRT1, pathways
that are known to be activated by exercise,
could rescue the phenotype. Following the
training period, muscle-R1KO mice were
more insulin sensitive and had increased
mitochondrial DNA content and citrate
synthase activity levels. This experiment
emphasized two points: (1) just how
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Previewseffective exercise is in reversing perturbed
insulin sensitivity and oxidative capacity
and (2) that because exercise activates
Ca2+, AMPK, SIRT1, and PGC1-a, the
possibility of targeting the adiponectin/
adipoR1 pathway as a therapeutic is tangi-
ble. It must be emphasized, however, that
discovering any single pharmacological
agent that will mimic the broad range of
exercise-related health benefits is indeed
remote, and, alas, we should not put our
joggers into mothballs just yet! However,
identifying and targeting specific common
biochemical and molecular components of
the exercise response are likely to lead to
viable drug therapies and prove beneficial
in the battle against such pathophysiol-
ogies as mitochondrial dysfunction in
obesity and insulin resistance.ACKNOWLEDGMENTS
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Dysregulation of autophagy contributes to aging and to diseases such as neurodegeneration, cardiomyop-
athy, and cancer. The paper by Yang et al. (2010) in this issue of Cell Metabolism indicates that defective au-
tophagymay also underlie impaired insulin sensitivity in obesity and that upregulating autophagy can combat
insulin resistance.Autophagy is responsible for the turnover
of long-lived proteins and of intracellular
structures that are damaged or function-
ally redundant. The process is essential
for the maintenance of cellular homeo-
stasis and is activated by starvation
(to supply ATP-producing substrates, e.g.,
amino acids) and other stress-inducing
conditions. Its dysregulation is involved
in many disorders and in aging (Meijer
and Codogno, 2009). In this issue of
Cell Metabolism, Yang et al. (2010) now
show that hepatic autophagy is defective
in obesity and diabetes and that its upre-
gulation improves insulin sensitivity.
During autophagy, part of the cytoplasm
is surrounded by a double membrane,presumably formed from the endoplasmic
reticulum (ER), to form an autophagosome
that then fuses with lysosomes, after which
the sequestered material is degraded. This
process requires the participation of au-
tophagy-related (ATG) proteins (see Meijer
and Codogno, 2009 for review).
Autophagy is inhibited by the insulin-
amino acid-mTOR signaling pathway
via both short-term and long-term regula-
tion mechanisms. Short-term inhibition
can be produced by the mammalian target
of rapamycin (mTOR) complex 1, which
causes phosphorylation and the inhibition
of ULK1 (the human homolog of yeast
ATG1). Long-term regulation occurs via
the transcription factors FoxO1 andFoxO3 (Liu et al., 2009), which control
the transcription of atg genes and become
phosphorylated and inhibited by insulin-
induced activation of protein kinase B
(Figure 1).
Recent evidence indicates that dysre-
gulation of autophagy is implicated in
obesity (characterized by ER stress,
insulin resistance, and glucose intoler-
ance; Hotamisligil, 2010) and in diabetes.
Mice fed a high-fat diet (HFD) have re-
duced hepatic autophagy (Liu et al.,
2009). However, autophagy, which is
essential for maintaining the structure
and function of b cells, is increased in
b cells during this period of HF feeding
(Ebato et al., 2008). In contrast, the11, June 9, 2010 ª2010 Elsevier Inc. 449
